Short Interest in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Decreases By 37.4%

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX - Get Free Report) was the recipient of a significant decrease in short interest in February. As of February 28th, there was short interest totalling 313,600 shares, a decrease of 37.4% from the February 13th total of 500,700 shares. Based on an average daily volume of 3,190,000 shares, the short-interest ratio is currently 0.1 days. Approximately 4.0% of the shares of the company are sold short.

Cumberland Pharmaceuticals Price Performance

Shares of CPIX stock traded down $0.07 during trading hours on Wednesday, hitting $5.07. The company's stock had a trading volume of 43,990 shares, compared to its average volume of 855,812. The business has a fifty day moving average of $4.18 and a 200-day moving average of $2.43. The stock has a market cap of $70.82 million, a price-to-earnings ratio of -6.58 and a beta of -0.18. Cumberland Pharmaceuticals has a twelve month low of $1.04 and a twelve month high of $7.25. The company has a current ratio of 1.13, a quick ratio of 0.99 and a debt-to-equity ratio of 0.41.

Cumberland Pharmaceuticals (NASDAQ:CPIX - Get Free Report) last released its quarterly earnings results on Tuesday, March 4th. The specialty pharmaceutical company reported ($0.03) EPS for the quarter. The business had revenue of $10.44 million during the quarter. Cumberland Pharmaceuticals had a negative net margin of 29.54% and a negative return on equity of 9.50%.

Remove Ads

Hedge Funds Weigh In On Cumberland Pharmaceuticals

An institutional investor recently raised its position in Cumberland Pharmaceuticals stock. Two Sigma Investments LP lifted its position in shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX - Free Report) by 94.3% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 37,649 shares of the specialty pharmaceutical company's stock after buying an additional 18,271 shares during the period. Two Sigma Investments LP owned 0.27% of Cumberland Pharmaceuticals worth $89,000 as of its most recent SEC filing. Institutional investors own 15.51% of the company's stock.

Analysts Set New Price Targets

Separately, StockNews.com upgraded shares of Cumberland Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Thursday, March 6th.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.